Search research articles
Contact Us
Filters
Showing results (81-90 of 101) with videos related to
Page
of 11
Sort By:
Genes, Chromosomes & Cancer
|
March 31, 2015
Dismantling papillary renal cell carcinoma classification: The heterogeneity of genetic profiles suggests several independent diseases
Alexandre Marsaud, Bérengère Dadone, Damien Ambrosetti, et al.
Seminars in Oncology
|
August 12, 2009
Other targetable sarcomas
Veridiana Pires de Camargo, Matt van de Rijn, Roberta Maestro, et al.
The Journal of Pathology. Clinical Research
|
August 9, 2016
HR23b expression is a potential predictive biomarker for HDAC inhibitor treatment in mesenchymal tumours and is associated with response to vorinostat
Michaela Angelika Ihle, Sabine Merkelbach-Bruse, Wolfgang Hartmann, et al.
Annals of Surgical Oncology
|
November 8, 2007
Cetuximab shows activity in colorectal cancer patients with tumors for which FISH analysis does not detect an increase in EGFR gene copy number
Antoine Italiano, Philippe Follana, François-Xavier Caroli, et al.
Genes, Chromosomes & Cancer
|
August 6, 2021
RBM10-TFE3 fusions: A FISH-concealed anomaly in adult renal cell carcinomas displaying a variety of morphological and genomic features: Comprehensive study of six novel cases
Ilaria Di Mauro, Bérengère Dadone-Montaudie, Mathilde Sibony, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
February 22, 2011
MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the bone
Fanny Dujardin, Matthieu Bui Nguyen Binh, Corinne Bouvier, et al.
International Journal of Cancer
|
June 19, 2015
SRC inhibition represents a potential therapeutic strategy in liposarcoma
Elisabeth Sievers, Marcel Trautmann, Dagmar Kindler, et al.
JAMA Dermatology
|
March 5, 2017
Association of Oncogenic Mutations in Patients With Advanced Cutaneous Squamous Cell Carcinomas Treated With Cetuximab
Alexandra Picard, Florence Pedeutour, Frédéric Peyrade, et al.
Cell Reports. Medicine
|
September 21, 2022
Targeting of c-MET and AXL by cabozantinib is a potential therapeutic strategy for patients with head and neck cell carcinoma
Anais Hagege, Esma Saada-Bouzid, Damien Ambrosetti, et al.
The American Journal of Surgical Pathology
|
August 28, 2007
Translocation-positive low-grade fibromyxoid sarcoma: clinicopathologic and molecular analysis of a series expanding the morphologic spectrum and suggesting potential relationship to sclerosing epithelioid fibrosarcoma: a study from the French Sarcoma Group
Louis Guillou, Jean Benhattar, Carole Gengler, et al.
Page
of 11
Search research articles
Search
Showing results (81-90 of 101) with videos related to
Sort By:
Page
of 11
Genes, Chromosomes & Cancer
|
March 31, 2015
Dismantling papillary renal cell carcinoma classification: The heterogeneity of genetic profiles suggests several independent diseases
Alexandre Marsaud, Bérengère Dadone, Damien Ambrosetti, et al.
Seminars in Oncology
|
August 12, 2009
Other targetable sarcomas
Veridiana Pires de Camargo, Matt van de Rijn, Roberta Maestro, et al.
The Journal of Pathology. Clinical Research
|
August 9, 2016
HR23b expression is a potential predictive biomarker for HDAC inhibitor treatment in mesenchymal tumours and is associated with response to vorinostat
Michaela Angelika Ihle, Sabine Merkelbach-Bruse, Wolfgang Hartmann, et al.
Annals of Surgical Oncology
|
November 8, 2007
Cetuximab shows activity in colorectal cancer patients with tumors for which FISH analysis does not detect an increase in EGFR gene copy number
Antoine Italiano, Philippe Follana, François-Xavier Caroli, et al.
Genes, Chromosomes & Cancer
|
August 6, 2021
RBM10-TFE3 fusions: A FISH-concealed anomaly in adult renal cell carcinomas displaying a variety of morphological and genomic features: Comprehensive study of six novel cases
Ilaria Di Mauro, Bérengère Dadone-Montaudie, Mathilde Sibony, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
February 22, 2011
MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the bone
Fanny Dujardin, Matthieu Bui Nguyen Binh, Corinne Bouvier, et al.
International Journal of Cancer
|
June 19, 2015
SRC inhibition represents a potential therapeutic strategy in liposarcoma
Elisabeth Sievers, Marcel Trautmann, Dagmar Kindler, et al.
JAMA Dermatology
|
March 5, 2017
Association of Oncogenic Mutations in Patients With Advanced Cutaneous Squamous Cell Carcinomas Treated With Cetuximab
Alexandra Picard, Florence Pedeutour, Frédéric Peyrade, et al.
Cell Reports. Medicine
|
September 21, 2022
Targeting of c-MET and AXL by cabozantinib is a potential therapeutic strategy for patients with head and neck cell carcinoma
Anais Hagege, Esma Saada-Bouzid, Damien Ambrosetti, et al.
The American Journal of Surgical Pathology
|
August 28, 2007
Translocation-positive low-grade fibromyxoid sarcoma: clinicopathologic and molecular analysis of a series expanding the morphologic spectrum and suggesting potential relationship to sclerosing epithelioid fibrosarcoma: a study from the French Sarcoma Group
Louis Guillou, Jean Benhattar, Carole Gengler, et al.
Page
of 11